Latest News
- 1/14/10
- Vicor Technologies Announces Exclusive Distribution Agreement for its PD2i Analyzer™ and First U.S. Physician Sale
- 1/5/10
- Vicor Technologies Forms Information Technology Function With Two Senior Hires; New Function To Support Staged Product Rollout Beginning January 2010
- 12/16/09
- Vicor Technologies' Financial Data Now Available via Standard & Poor's Market Access Program
- 12/10/09
- Vicor Technologies’ PD2i® Nonlinear Algorithm Selected for Use in Screening Initiative to Identify Youth at Risk of Sudden Cardiac Death
- 12/3/09
- Heart Rate Variability Gains Popularity as Cost-Effective Diagnostic
- 11/24/09
- Vicor Technologies Announces Beta Test Site Installation of Application Service Provider Distribution Model
- 11/19/09
- USAISR Researcher Dr. Andriy Batchinsky Identifies Vicor’s PD2i® Nonlinear Algorithm As Most Promising Diagnostic for In-Field Trauma Triage In Presentation at the American Heart Association's Resuscitation Science Symposium 2009
- 11/16/09
- Vicor Technologies Announces Filing of 10-Q, Ends Quarter With Strongest Balance Sheet in Several Years
- 10/26/09
- Vicor Technologies Shareholder Letter Highlights Progress Toward Commercialization
- 10/06/09
- Trial Findings for Vicor Technologies' PD2i Vital Sign™ Diagnostic to Be Presented at the American Heart Association's Resuscitation Science Symposium 2009
- 09/29/09
- Vicor Technologies Issued Australian Patent for Its Altered State Physiology Drug Development Platform
- 09/22/09
- Vicor’s PD2i® Nonlinear Algorithm to Be Tested on Trauma Patients in U.S. Army's New Critical Combat Care Engineering (C3E) Program Area
- 09/15/09
- Filmmaker John Hughes’ Recent Untimely Death is a Call for Better Understanding of Sudden Cardiac Death, the Leading Cause of Natural Death in the U.S.
- 08/25/09
- Original Research Using Vicor’s PD2i® Nonlinear Algorithm Published in Therapeutics and Clinical Risk Management
- 08/19/09
- Vicor Technologies Announces International Distribution Agreement; Revenues Expected to Commence in 4Q09
- 08/11/09
- Vista Partners Initiates Coverage on Vicor Technologies With $2.96 Price Target
- 08/07/09
- Trial Findings for Vicor Technologies' PD2i-VS Vital Sign™ Diagnostic to Be Presented at the ATACCC 2009 Conference
- 07/21/09
- Vicor Technologies Announces Sale of Convertible Notes
- 05/28/09
- Vicor Technologies Announces OEM Agreement
- 05/27/09
- Vicor Technologies CEO Discusses New Developments with CEO·CFO
- 05/07/09
- Vicor Technologies Announces Sale of Convertible Notes
- 03/23/09
- Vicor Technologies Retains Cameron Associates for Investor Relations Services
- 03/18/09
- Vicor Technologies Begins Major Sudden Cardiac Death Study Under Research Agreement With University of Rochester and Catalan Institute of Cardiovascular Sciences
- 01/13/09
- Vicor Technologies' Chief Medical Officer Interviewed by EP Lab Digest
- 01/08/09
- Vicor Technologies Announces Receipt of Eurasian Patent for Its Altered State Physiology Drug Development Platform
- 01/07/09
- Vicor Technologies CEO David Fater Discusses Company's Diagnostics Development Strategy With CEOroadshow.com in Exclusive Online Audio Interview
- 01/06/09
- Vicor Technologies Announces Receipt of 510(K) Approval to Market its PD2i Analyzer™
